NEOS Investment Management LLC Has $639,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

NEOS Investment Management LLC lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 30.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,231 shares of the company's stock after selling 7,092 shares during the period. NEOS Investment Management LLC's holdings in CRISPR Therapeutics were worth $639,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CRSP. Highline Wealth Partners LLC bought a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Western Pacific Wealth Management LP lifted its holdings in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $40,000. Spire Wealth Management grew its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after acquiring an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC bought a new position in CRISPR Therapeutics during the fourth quarter worth $80,000. Institutional investors own 69.20% of the company's stock.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of research reports. Barclays increased their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Needham & Company LLC reissued a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Royal Bank of Canada cut their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a report on Wednesday, February 12th. Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. Finally, HC Wainwright restated a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $73.11.

Remove Ads

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John Greene bought 7,000 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 26th. The shares were bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares of the company's stock, valued at $313,950. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Trading Down 0.0 %

Shares of CRISPR Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $32.65. 3,076,063 shares of the stock were exchanged, compared to its average volume of 1,578,570. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -7.47 and a beta of 1.85. CRISPR Therapeutics AG has a fifty-two week low of $30.20 and a fifty-two week high of $67.88. The firm has a 50-day simple moving average of $42.15 and a 200 day simple moving average of $44.71.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.